CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sahajanand Medical Technologies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sahajanand Medical Technologies Ltd
Sahajanand Estate
Wakhariawadi, Near Dabholi
Phone: +91 2613060606p:+91 2613060606 SURAT, 395004  India Ticker: SMTSMT
Business Summary
Sahajanand Medical Technologies Limited is an India-based medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. The Company is engaged in the development of Class III and Class C/D medical devices, with an emphasis on Vascular Intervention (VI) and Structural Heart (SH). Its portfolio of VI products includes coronary intervention products, such as coronary stents and coronary balloons, SH products include Trans-Catheter Aortic Valve (TAVI) and Occluders, and others, including its own brand of renal stents, peripheral Drug Coated Balloons (DCBs) and other trading products. It operates through the Cardiovascular Devices segment. It has built a clinical foundation for its flagship products, including Supraflex Cruz, Hydra, Sironity Drug-coated PTCA Balloon, Pipit and Cocoon, supported by 75 clinical studies (comprising 66 completed studies and nine ongoing studies). It marketed its products in 77 countries.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
Yes--Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20263/31/2026Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Managing Director (Promoter) Bhargav D.Kotadia 33 4/1/2025 5/6/2013
Chief Financial Officer Amit K.Khandelia 2/1/2024 2/1/2024
Company Secretary DeepshikhaSinghal 6/20/2023 6/20/2023
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,605 (As of 6/30/2026)
Outstanding Shares: 101,646,778 (As of 6/30/2026)
Stock Exchange: NSE
Fax Number: +91 2613060607


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 27, 2026